目的 了解天津市津南区咸水沽医院降糖类药物的使用情况和变化趋势，为促使临床合理应用提供参考。方法 采用回顾性分析方法，对2015-2017年天津市津南区咸水沽医院门诊降糖类药物的销售金额、使用频度（DDDs）、日均费用（DDC）和排序比（B/A）等进行统计并排序、分析。结果 注射类和口服类降糖药物的销售金额和DDDs均呈先上升后下降的趋势。注射类降糖药的销售金额、DDDs都稳居第1位。口服类降糖药中，α-葡萄糖苷酶抑制剂的销售金额、DDDs都高居榜首，其次是非磺酰脲类促泌剂。阿卡波糖片的销售金额、DDDs排序始终居首位，其次是瑞格列奈片，销售金额居第2位。胰岛素类各品种的金额和DDDs排序无明显浮动，排名基本稳定。其中长效胰岛素类似物的销售金额排名逐年上升，2017年排名跃居第1位，预混胰岛素类似物的DDDs排名始终居首位。注射类和口服类降糖药的B/A比值均接近1.00，说明患者同步性良好。结论 天津市津南区咸水沽医院降糖类药物使用基本合理，个别药物如阿卡波糖片的使用量明显超过指南中推荐的一线用药二甲双胍类。

Objective To understand the usage and changing trend of antidiabetic drugs in Jinnan Xianshuigu Hospital of Tianjin City, so as to provide basis for the rational application of antidiabetic drugs in clinic. Methods A retrospective analysis method was used to analyze the sales amount, frequency of use (DDDs), daily average cost (DDC), and B/A of Department of Outpatient of Tianjin Xianshuigu Hospital from 2015 to 2017. Results The sales volume and DDDs of injectable and oral antidiabetic drugs showed a trend of first increasing and then decreasing. Sales amount and DDDs of injectable antidiabetic drugs were ranked the first. Sales amount and DDDs of α-glucosidase inhibitor in oral antidiabetic drugs were ranked the top, followed by non-sulfonylurea secretagogues. Sales amount and DDDs of Acarbose Tablets were always ranked first, followed by Repaglinide Tablets in second place. The sequence of sales amount and DDDs of various types of insulin had no obvious floating, and the rankings were basically stable. Among them, the sales amount sequence of long-acting insulin analogs increased year by year, and sales amount of long-acting insulin analogs were ranked the first in 2017. DDDs of premixed insulin analogues were always ranked the first. The B/A ratio of injectable and oral antidiabetic drugs were close to 1.00, indicating that patients had good synchronization. Conclusion The use of antidiabetic drugs in Jinnan Xianshuigu Hospital of Tianjin City is basically rational. The use of Acarbose Tablets significantly exceeds the recommended first-line metformin in the guidelines.